-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450

Benzinga·09/29/2026 17:53:02
Diffusion vocale
Citigroup analyst Vivek Agrawal upgrades Dr Reddy's Laboratories (NYSE:RDY) from Sell to Buy and raises the price target from $1040 to $1450.